CD1A

Across TCGA pan-cancer cohorts, CD1A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CD1A data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD1A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC and PDAC are the cancer types where CD1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.530	0.964	.009	10	view →
PDAC	DFS	Median	All	0.955	0.709	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CD1A–HNSC (DFS)

Open the HNSC breakdown →